Ranolazine Krka is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
Tapentadol Krka is indicated for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics.
Pramipexole Krka is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).
Janssen R&D has submitted a New Drug Application to the FDA seeking approval for a once-daily fixed-dose antiretroviral combination tablet...
The purpose of this study is to evaluate the single-dose pharmacokinetics and bioequivalence of darunavir 800 mg when administered as...